Wisevoter
U.S.

Tradipitant Trial Shows Promise Against GLP-1 Side Effects

A Phase 3 study finds that tradipitant significantly reduces vomiting in patients taking a 1 mg dose of semaglutide.

Updated on Oct. 27, 2026 in Weight Loss

A close-up view of a clear glass volumetric flask on a metallic laboratory surface, evoking medical clinical research.
Vanda Pharmaceuticals reports that its drug tradipitant reduced vomiting by 27 percent in a Phase 3 study of patients taking semaglutide. AI Illustration. Upload story photo >

Live Poll

Do you believe new treatments to reduce side effects will make you more likely to use medications?

Vanda Pharmaceuticals released results from its Phase 3 Study 3601 showing that tradipitant reduced any vomiting by 27% among participants taking a 1 mg dose of semaglutide. The company now plans to submit a supplemental New Drug Application to the FDA for this new indication.

Why it matters

Nausea and vomiting are primary drivers for why patients discontinue popular GLP-1 weight loss therapies. Addressing these side effects could improve patient adherence to long-term treatment regimens.

The Study 3601 trial included 142 participants receiving tradipitant and 164 receiving a placebo. The drug showed an 81% relative reduction in extreme vomiting and a 60% relative reduction in frequent multiday vomiting compared to the placebo group.

The players

Vanda Pharmaceuticals

This biopharmaceutical company focuses on the development and commercialization of innovative therapies to address significant unmet medical needs.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs and medical devices.

The details

Tradipitant functions by blocking substance P signaling in central emetic pathways to mitigate gastrointestinal distress. The trial focused on patients receiving a 1 mg dose of semaglutide, a medication also used for metabolic dysfunction-associated steatohepatitis.

Timeline

  1. August 2025: The FDA approved semaglutide 2.4 mg for noncirrhotic MASH.

  2. December 2025: Tradipitant received FDA approval for motion-induced vomiting.

  3. October 27, 2026: Results from Study 3601 were formally announced.

  4. 2027: Vanda Pharmaceuticals expects to meet with the FDA to discuss study outcomes.

Health Landscape

This study follows a pattern set by the FDA approval of semaglutide for metabolic dysfunction-associated steatohepatitis as researchers seek to expand the clinical utility and tolerability of GLP-1 therapies. Improving drug tolerance remains a critical goal in maximizing the efficacy of these widely prescribed treatments.

If approved, this therapy could provide a new way for patients to manage the gastrointestinal side effects that often cause them to stop their weight loss medications. This could make it easier for individuals to maintain their prescribed health routines over the long term.

The takeaway

Managing side effects like nausea is crucial for the long-term success of GLP-1 therapies in the United States. Patients struggling with current treatment regimens should consult their healthcare provider about emerging options and adherence strategies.

What happens next

Vanda Pharmaceuticals expects to meet with the FDA in 2027 to discuss the results of Study 3601.

Further reading

For more on the current landscape of metabolic treatments, visit the Weight Loss section.

Live Poll

Do you believe new treatments to reduce side effects will make you more likely to use medications?